Apollomics (APLM) Competitors $6.74 +0.09 (+1.35%) Closing price 06/10/2025 03:59 PM EasternExtended Trading$6.55 -0.19 (-2.88%) As of 06/10/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. ALLK, BCAB, DYAI, CVKD, EGRX, INKT, PASG, VOR, DARE, and ABVCShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Allakos (ALLK), BioAtla (BCAB), Dyadic International (DYAI), Cadrenal Therapeutics (CVKD), Eagle Pharmaceuticals (EGRX), MiNK Therapeutics (INKT), Passage Bio (PASG), Vor Biopharma (VOR), Daré Bioscience (DARE), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Allakos BioAtla Dyadic International Cadrenal Therapeutics Eagle Pharmaceuticals MiNK Therapeutics Passage Bio Vor Biopharma Daré Bioscience ABVC BioPharma Apollomics (NASDAQ:APLM) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Is APLM or ALLK more profitable? Apollomics' return on equity of 0.00% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Allakos N/A -140.87%-86.22% Which has stronger earnings & valuation, APLM or ALLK? Apollomics has higher revenue and earnings than Allakos. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M6.09-$172.60MN/AN/AAllakosN/AN/A-$185.70M-$1.32-0.25 Do institutionals and insiders believe in APLM or ALLK? 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 16.1% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor APLM or ALLK? In the previous week, Apollomics had 2 more articles in the media than Allakos. MarketBeat recorded 2 mentions for Apollomics and 0 mentions for Allakos. Allakos' average media sentiment score of 0.00 beat Apollomics' score of -1.00 indicating that Allakos is being referred to more favorably in the news media. Company Overall Sentiment Apollomics Negative Allakos Neutral Does the MarketBeat Community prefer APLM or ALLK? Allakos received 179 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% AllakosOutperform Votes18358.84% Underperform Votes12841.16% Do analysts rate APLM or ALLK? Allakos has a consensus target price of $2.00, indicating a potential upside of 507.72%. Given Allakos' stronger consensus rating and higher probable upside, analysts clearly believe Allakos is more favorable than Apollomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more risk and volatility, APLM or ALLK? Apollomics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. SummaryApollomics and Allakos tied by winning 7 of the 14 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.43M$6.83B$5.57B$8.66BDividend YieldN/A2.50%5.27%4.19%P/E RatioN/A8.7927.2020.17Price / Sales6.09263.51412.92161.90Price / CashN/A65.8538.2534.64Price / Book0.146.677.114.72Net Income-$172.60M$143.49M$3.23B$247.80M7 Day Performance3.85%6.34%4.61%3.36%1 Month Performance18.66%15.43%13.35%9.71%1 Year Performance-70.84%6.87%31.75%14.41% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics0.3534 of 5 stars$6.74+1.4%N/A-70.8%$7.34M$1.22M0.0045Gap DownALLKAllakos3.9254 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190BCABBioAtla2.5052 of 5 stars$0.51+5.4%$5.00+884.8%-67.5%$29.66M$11M-0.3060Gap UpDYAIDyadic International2.4638 of 5 stars$0.98-0.8%$6.00+510.8%-52.9%$29.56M$3.34M-4.277CVKDCadrenal Therapeutics2.9303 of 5 stars$15.00-0.7%$32.00+113.3%N/A$29.51MN/A-2.254Positive NewsEGRXEagle PharmaceuticalsN/A$2.25+2.3%N/A-41.0%$29.22M$257.55M0.00100Gap DownINKTMiNK Therapeutics2.7987 of 5 stars$7.27+0.1%$37.50+416.0%-22.9%$28.92MN/A-1.8630News CoveragePASGPassage Bio3.0527 of 5 stars$0.46+9.1%$7.50+1,525.8%-56.0%$28.67MN/A-0.39130Positive NewsVORVor Biopharma3.3778 of 5 stars$0.22-0.4%$7.06+3,066.1%-82.3%$27.85MN/A-0.14140Gap UpDAREDaré Bioscience1.6863 of 5 stars$3.13-2.2%$12.00+283.4%-44.6%$27.70M$25,909.00-5.3030Analyst RevisionABVCABVC BioPharma0.6126 of 5 stars$1.62+5.2%N/A+107.8%$27.51M$508,384.00-1.8830Positive News Related Companies and Tools Related Companies Allakos Competitors BioAtla Competitors Dyadic International Competitors Cadrenal Therapeutics Competitors Eagle Pharmaceuticals Competitors MiNK Therapeutics Competitors Passage Bio Competitors Vor Biopharma Competitors Daré Bioscience Competitors ABVC BioPharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
